[CAS NO. 6054-98-4] OlsalazineDisodium
PRODUCTS SPECIFICATIONS [6054-98-4]
DESCRIPTION [6054-98-4]
Overview
| MDL | MFCD00013300 |
|---|---|
| Molecular Weight | 346.20 |
| Molecular Formula | C14H8N2Na2O6 |
| SMILES | O=C(O[Na])C1=C(O)C=CC(/N=N/C2=CC(C(O[Na])=O)=C(O)C=C2)=C1 |
Summary
Olsalazine Disodium is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Target: Antibacterial Olsalazine Disodium is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Olsalazine Disodium is potent inhibitors of human intestinal macrophages chemotaxis to LTB4 with IC50 of 0.39 mM. Olsalazine Disodium (0.4 mM) inhibits the superoxide radical production generated by phorbol myristate acetate (PMA)-activated neutrophils or by xanthine-xanthine oxidase reaction by reduction of 31% and 73%, respectively. Olsalazine Disodium inhibits tumor growth in a rodent model of colorectal cancer . In 1,2-dimethylhydrazine-treated rats, Olsalazine (25 mg/kg/day) decreases number and volume of tumors by 58.17% and 62.67%, respectively. Administration of Olsalazine (Disodium) induces a 1.7-fold times increase in the number of apoptotic cells, companied with a reduction of 42.4% in cell proliferation rate.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00004288 | National Center for Research Resources (NCRR)|University of Rochester|Office of Rare Diseases (ORD) |
Ankylosing Spondylitis
|
May 1996 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
H 2 O : 50 mg/mL ( 144.43 mM ; Need ultrasonic)
DMSO : 20 mg/mL ( 57.77 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8885 mL | 14.4425 mL | 28.8850 mL |
| 5 mM | 0.5777 mL | 2.8885 mL | 5.7770 mL |
| 10 mM | 0.2889 mL | 1.4443 mL | 2.8885 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 15 mg/mL (43.33 mM); Clear solution; Need ultrasonic
References
- [1] Nielsen, O.H., H.W. Verspaget, and J. Elmgreen, Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther, 1988. 2(3): p. 203-11.
- [2] Gionchetti, P., et al., Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci, 1991. 36(2): p. 174-8.
- [3] Brown, W.A., et al., 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci, 2000. 45(8): p. 1578-84.
Synonyms